doi: 10.1001/jama.2024.16432.
The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits
Affiliations
- PMID: 39240544
- DOI: 10.1001/jama.2024.16432
Item in Clipboard
The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits
JAMA.
.
No abstract available
Plain language summary
This Medical News article discusses the latest research about the use of nirmatrelvir-ritonavir, sold as Paxlovid, to treat COVID-19 and, possibly, to prevent or treat long COVID.
Similar articles
-
Paxlovid for treatment of COVID-19.Med Lett Drugs Ther. 2022 Jan 24;64(1642):9-10. Med Lett Drugs Ther. 2022. PMID: 35134040 No abstract available.
-
Treatment of COVID-19 in high-risk outpatients.Med Lett Drugs Ther. 2022 Feb 7;64(1643):e1. Med Lett Drugs Ther. 2022. PMID: 35134051 No abstract available.
-
From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid.JAMA. 2022 Jun 28;327(24):2380-2382. doi: 10.1001/jama.2022.9925. JAMA. 2022. PMID: 35675094 No abstract available.
-
A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir.Clin Pharmacokinet. 2024 Jan;63(1):27-42. doi: 10.1007/s40262-023-01339-y. Epub 2024 Jan 4. Clin Pharmacokinet. 2024. PMID: 38177893 Free PMC article. Review.
-
Fixing the Achilles Heel of Pfizer's Paxlovid for COVID-19 Treatment.J Med Chem. 2024 Jul 25;67(14):11656-11661. doi: 10.1021/acs.jmedchem.4c01342. Epub 2024 Jul 5. J Med Chem. 2024. PMID: 38967233 Free PMC article. Review.
Cited by
-
COVID-19 Antiviral Medication Use Among Pregnant and Recently Pregnant US Outpatients.Clin Infect Dis. 2025 Mar 17;80(3):512-519. doi: 10.1093/cid/ciae580. Clin Infect Dis. 2025. PMID: 39907453 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
